Moderna short sellers face $4.8 billion loss amid record stock jump
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Moderna (MRNA) PT Raised to $89 at Morgan Stanley
August 19, 2026 4:23 PM EDTMorgan Stanley analyst Terence Flynn raised the price target on Moderna (NASDAQ: MRNA) to $89.00 (from $39.00) while maintaining a Equalweight rating.
The analyst comments "We are Equal-weight Moderna. While we believe there is long-term upside for Moderna, we believe the significant valuation increase... More
